Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | MAOB | P27338 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
| ▸ | CNR2 | P34972 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30865951 | 0.81 | ALOX5 (0.72) | ALOX5ALDH1A1GAAPOLBKMT2A | |
| SCHEMBL12069952 | 0.80 | KMT2A (0.84) | ALOX5ALDH1A1MAPTPOLBKMT2A | |
| SCHEMBL13836513 | 0.79 | ALOX5 (0.72) | ALOX5ALDH1A1GAAPOLBKMT2A | |
| SCHEMBL16227143 | 0.79 | ALDH1A1 (0.73) | ALDH1A1LMNAMAPTMAOBHTT | |
| SCHEMBL19357185 | 0.78 | MGLL (0.74) | ALDH1A1LMNAMAPTMAOBKMT2A | |
| SCHEMBL2153286 | 0.78 | ALOX5 (1.00) | ALOX5ALDH1A1LMNAMAPTHTT | |
| SCHEMBL31350986 | 0.77 | MAOB (1.00) | ALDH1A1MAPTMAOBKMT2A | |
| SCHEMBL12488830 | 0.77 | ALOX5 (0.71) | ALOX5ALDH1A1POLBKMT2A | |
| SCHEMBL9659506 | 0.77 | HTT (0.61) | TDP1ALDH1A1MAPTMAOBHTT | |
| SCHEMBL13836598 | 0.77 | ALOX5 (0.67) | ALOX5ALDH1A1LMNAHTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295890-A1 | GLYCOSAMINOGLYCAN INHIBITORS | Zacharon Pharmaceutical, Inc. (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2011082175-A2 | GLYCOSAMINOGLYCAN INHIBITORS | ZACHARON PHARMACEUTICALS, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295890-A1 | GLYCOSAMINOGLYCAN INHIBITORS | CSGALNACT1, FUT5, ST3GAL3 | TDP1 3893/4885ALOX5 3758/4885ALDH1A1 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.